Skip to content
The Policy VaultThe Policy Vault

Imkeldi (imatinib oral solution) — Medica

Myelodysplastic/myeloproliferative disease

Initial criteria

  • age ≥ 18 years
  • Condition associated with PDGFR gene rearrangements

Approval duration

1 year